Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition

Journal of Cellular Physiology

Volumn 223, Issue 2, 2010, Pages 317-326

  Selige, Jens ^a   Tenor, Hermann ^a   Hatzelmann, Armin ^a   Dunkern, Torsten ^a  

^a Nycomed GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYCLIC AMP; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; MESSENGER RNA; PHOSPHODIESTERASE IV; PROSTAGLANDIN E2;

ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; LUNG FIBROBLAST; MITOGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SIGNAL TRANSDUCTION;

BENZAMIDES; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; GENES, CDC; GROWTH SUBSTANCES; HUMANS; INTERLEUKIN-1BETA; LUNG; PULMONARY FIBROSIS; PYRIDAZINES; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 77950854863     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22037     Document Type: Article

References (60)

1. Agostini C, Gurrieri C. 2006. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3:357-363.
2. American Thoracic Society. 2000. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161:646-664.
3. Andersson-Sjoland A, de Alba CG, Nihlberg K, Becerril C, Ramirez R, Pardo A, Westergren-Thorsson G, Selman M. 2008. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 40:2129-2140.
4. Barnes PJ. 2003. New concepts in chronic obstructive pulmonary disease. Annu Rev Med 54:113-129.
5. Bauer AC, Schwabe U. 1980. An improved assay of cyclic 3′,5′-nucleotide phosphodiesterases with QAE-Sephadex columns. Naunyn Schmiedebergs Arch Pharmacol 311:193-198.
6. Bjornsdottir US, Cypcar DM. 1999. Asthma: An inflammatory mediator soup. Allergy 54:55-61.
7. Bond M, Fabunmi RP, Baker AH, Newby AC. 1998. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-kappa B. FEBS Lett 435:29-34.
8. Borbe HO, Hilboll G, Prop G. 1986. Inhibition of human platelet aggregation by motapizone via an increase in intracellular cAMP. Agents Actions Suppl 20:249-257.
9. Bourcier T, Dockter M, Hassid A. 1995. Synergistic interaction of interleukin-1 beta and growth factors in primary cultures of rat aortic smooth muscle cells. J Cell Physiol 164:644-657.
10. Chung KF. 2001. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl 34:50s-59s.
11. Conti M, Beavo J. 2007. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511.
12. Cortijo J, Iranzo A, Milara X, Mata M, Cerda-Nicolas M, Ruiz-Sauri A, Tenor H, Hatzelmann A, Morcillo EJ. 2009. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol 156:534-544.
13. Cozzolino F, Torcia M, Aldinucci D, Ziche M, Almerigogna F, Bani D, Stern DM. 1990. Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci USA 87:6487-6491.
14. Dempsey OJ, Kerr KM, Gomersall L, Remmen H, Currie GP. 2006. Idiopathic pulmonary fibrosis: An update. QJM 99:643-654.
15. Dumaz N, Marais R. 2005. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J 272:3491-3504.
16. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A. 2007. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 572:12-22.
17. Giri SN,Hyde DM, Hollinger MA. 1993. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 48:959-966.
18. Goldring MB, Birkhead J, Sandell LJ, Kimura T, Krane SM. 1988. Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest 82:2026-2037. (Pubitemid 19054951)
19. Gross TJ, Hunninghake GW. 2001. Idiopathic pulmonary fibrosis.N Engl J Med 345:517-525.
20. Haag S, Warnken M, Juergens UR, Racke K. 2008. Role of Epac 1 in mediating anti-proliferative effects of prostanoid EP(2) receptors and cAMP in human lung fibroblasts. Naunyn Schmiedebergs Arch Pharmacol 378:617-630.
21. Hatzelmann A, Schudt C. 2001. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279. (Pubitemid 32242587)
22. Herrmann M, Selige J, Raffael S, Sachs G, Brambilla A, Klein T. 2007. Systematic expression profiling of the gastric H+/K+ ATPase in human tissue. Scand J Gastroenterol 42:1275-1288. (Pubitemid 47537078)
23. Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM, Peters-Golden M. 2007. Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol Lung Cell Mol Physiol 292:L405-L413. (Pubitemid 46271592)
24. Huang SK, Wettlaufer SH, Chung J, Peters-Golden M. 2008. Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Epac-1. Am J Respir Cell Mol Biol 39:482-489.
25. Inoue Y, King TE, Jr., Barker E, Daniloff E, Newman LS. 2002. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med 166:765-773. (Pubitemid 34971864)
26. Jeffery PK. 2001. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 164:S28-S38.
27. Khalil N, Xu YD, O'Connor R, Duronio V. 2005. Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J Biol Chem 280:43000-43009. (Pubitemid 43049264)
28. Kida Y, Kobayashi M, Suzuki T, Takeshita A, Okamatsu Y, Hanazawa S, Yasui T, Hasegawa K. 2005. Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappa B in human gingival fibroblasts. Cytokine 29:159-168. (Pubitemid 40126234)
29. Kohyama T, Liu X, Zhu YK, Wen FQ, Wang HJ, Fang Q, Kobayashi T, Rennard SI. 2002. Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase. Am J Respir Cell Mol Biol 27:487-494.
30. Kohyama T, Liu X, Wen FQ, Kobayashi T, Fang Q, Abe S, Cieslinski L, Barnette MS, Rennard SI. 2004. Cytokines modulate cilomilast response in lung fibroblasts. Clin Immunol 111:297-302. (Pubitemid 38739323)
31. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. 2001. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 107:1529-1536. (Pubitemid 32574639)
32. Kotaru C, Schoonover KJ, Trudeau JB, Huynh ML, Zhou X, Hu H, Wenzel SE. 2006. Regional fibroblast heterogeneity in the lung: Implications for remodeling. Am J Respir Crit Care Med 173:1208-1215. (Pubitemid 43848390)
33. Kranenburg AR, Willems-Widyastuti A, Mooi WJ, Saxena PR, Sterk PJ, de Boer WI, Sharma HS. 2005. Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1, FGF-2, and FGFR-1. J Pathol 206:28-38. (Pubitemid 40613431)
34. L'Allemain G, Lavoie JN, Rivard N, Baldin V, Pouyssegur J. 1997. Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts. Oncogene 14:1981-1990. (Pubitemid 27217811)
35. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. 2005. Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol 32:311-318. (Pubitemid 40478306)
36. Laulederkind SJ, Kirtikara K, Raghow R, Ballou LR. 2000. The regulation of PGE(2) biosynthesis in MG-63 osteosarcoma cells by IL-1 and FGF is cell density-dependent. Exp Cell Res 258:409-416. (Pubitemid 30483519)
37. Lee HT, Kay EP. 2003. Regulatory role of cAMP on expression of Cdk4 and p27(Kip1) by inhibiting phosphatidylinositol 3-kinase in corneal endothelial cells. Invest Ophthalmol Vis Sci 44:3816-3825. (Pubitemid 37047951)
38. Liu X, Ostrom RS, Insel PA. 2004. cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am J Physiol Cell Physiol 286:C1089-C1099. (Pubitemid 38506924)
39. Musa NL, Ramakrishnan M, Li J, Kartha S, Liu P, Pestell RG, Hershenson MB. 1999. Forskolin inhibits cyclin D1 expression in cultured airway smooth-muscle cells. Am J Respir Cell Mol Biol 20:352-358. (Pubitemid 129504897)
40. Norioka K, Mitaka T, Mochizuki Y, Hara M, Kawagoe M, Nakamura H. 1994. Interaction of interleukin-1 and interferon-gamma on fibroblast growth factor-induced angiogenesis. Jpn J Cancer Res 85:522-529. (Pubitemid 2083353)
41. Palmer JN, Hartogensis WE, Patten M, Fortuin FD, Long CS. 1995. Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest 95:2555-2564.
42. Phan SH. 2008. Biology of fibroblasts and myofibroblasts. Proc Am Thorac Soc 5:334-337.
43. Piguet PF, Vesin C, Grau GE, Thompson RC. 1993. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited inmice by bleomycin or silica. Cytokine 5:57-61. (Pubitemid 23098835)
44. Rabe KF, Tenor H, Dent G, Schudt C, Liebig S, Magnussen H. 1993. Phosphodiesterase isozymes modulating inherent tone in human airways: Identification and characterization. Am J Physiol 264:L458-L464. (Pubitemid 23150827)
45. Raeburn D, Underwood SL, Lewis SA, Woodman VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE,Webber SE. 1994. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 113:1423-1431. (Pubitemid 24364430)
46. Raines EW, Dower SK, Ross R. 1989. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 243:393-396.
47. Sanchez T, Moreno JJ. 2002. Role of EP(1) and EP(4) PGE(2) subtype receptors in serum-induced 3T6 fibroblast cycle progression and proliferation. Am J Physiol Cell Physiol 282:C280-C288.
48. Scherle PA, Pratta MA, Feeser WS, Tancula EJ, Arner EC. 1997. The effects of IL-1 on mitogen-activated protein kinases in rabbit articular chondrocytes. Biochem Biophys Res Commun 230:573-577.
49. Schmitt JM, Stork PJ. 2001. Cyclic AMP-mediated inhibition of cell growth requires the small G protein Rap1. Mol Cell Biol 21:3671-3683.
50. Spurzem JR, Rennard SI. 2005. Pathogenesis of COPD. Semin Respir Crit Care Med 26:142-153.
51. Strieter RM. 2005. Pathogenesis and natural history of usual interstitial pneumonia: The whole story or the last chapter of a long novel. Chest 128:526S-532S.
52. Stuart WD, Maeda S, Khera P, Fagin JA, Clemens TL. 2000. Parathyroid hormone-related protein induces G1 phase growth arrest of vascular smooth muscle cells. Am J Physiol Endocrinol Metab 279:E60-E67.
53. Thompson WJ, Terasaki WL, Epstein PM, Strada SJ. 1979. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cyclic Nucleotide Res 10:69-92.
54. Togo S, Holz O, Liu X, Sugiura H, Kamio K, Wang X, Kawasaki S, Ahn Y, Fredriksson K, Skold CM, Mueller KC, Branscheid D, Welker L,Watz H, Magnussen H, Rennard SI. 2008. Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. Am J Respir Crit Care Med 178:248-260.
55. Togo S, Liu X, Wang X, Sugiura H, Kamio K, Kawasaki S, Kobayashi T, Ertl RF, Ahn Y, Holz O, Magnussen H, Fredriksson K, Skold CM, Rennard SI. 2009. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol 296:L959-L969.
56. Vancheri C, Sortino MA, Tomaselli V, Mastruzzo C, Condorelli F, Bellistri G, Pistorio MP, Canonico PL, Crimi N. 2000. Different expression of TNF-alpha receptors and prostaglandin E(2)Production in normal and fibrotic lung fibroblasts: Potential implications for the evolution of the inflammatory process. Am J Respir Cell Mol Biol 22:628-634.
57. White KE, Ding Q, Moore BB, Peters-Golden M,Ware LB, Matthay MA, Olman MA. 2008. Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors. J Immunol 180:637-646.
58. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. 1995. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 95:1861-1868.
59. Zaccolo M, Di Benedetto G, Lissandron V, Mancuso L, Terrin A, Zamparo I. 2006. Restricted diffusion of a freely diffusible second messenger: Mechanisms underlying compartmentalized cAMP signalling. Biochem Soc Trans 34:495-497.
60. Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN. 1993. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 150:4188-4196.